Roche said it would increase its dividend after its hemophilia injection Hemlibra and multiple sclerosis treatment Ocrevus lifted sales in the first nine months of the year.
Roche said it would increase its dividend after its hemophilia injection Hemlibra and multiple sclerosis treatment Ocrevus lifted sales in the first nine months of the year.